Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

27.09 +1.21 (+4.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bridgebio Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
BridgeBio Pharma: Q1 Earnings Insights
Via Benzinga
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
What 5 Analyst Ratings Have To Say About BridgeBio Pharma
Via Benzinga
2 Best Growth Stocks to Buy in April
Takeover interest is spurring these two biotech stocks higher. 
Via The Motley Fool
4 Analysts Have This to Say About BridgeBio Pharma
Via Benzinga
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering. 
Via Benzinga
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
Via Benzinga
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Top 5 Best And Worst U.S. Industry ETFs In Q1 2023: AI and Bank Turmoil Shaped Stock Returns
The first quarter of 2023 was positive for the U.S. stock market as a whole, with the S&P 500 index faithfully tracked by the SPDR S&P 500 ETF Trust (ARCA: SPY), rising by 6%. 
Via Benzinga
Stocks Rise As Investors Bet On Bank Recovery
Stocks are swinging higher today, as bond yields retreat and Wall Street bets that the worst of the regional banking crisis is in the rearview mirror. 
Via Talk Markets
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
Benzinga 
Via Benzinga
Rare Disease Player BridgeBio Pharma Draws Attention Of Big Pharma Companies, Gets Takeover Interest
BridgeBio Pharma Inc (NASDAQ: BBIO) is reportedly attracting takeover interest as some large pharmaceutical companies are studying a potential acquisition of the biotech firm.  
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope
BridgeBio’s recent volatility is a perfect example of how good news often turns into bad news for biopharmaceutical companies. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Why BridgeBio Pharma Shares Are Falling Sharply
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading lower by 15.8% to $15.62 Wednesday morning after the company priced an offering of 8.82 million shares at $17 per share. 
Via Benzinga
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
Via Benzinga
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Tesla, Amazon, Ambrx, BridgeBio, Azul: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Why BioMarin Shares Are Plunging Today?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition. 
Via Benzinga
These 2 Biotech Stocks Made Big Monday Moves
Find out which was the winner and which was the loser. 
Via The Motley Fool
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.